Sickle Cell Disease - Market Insights, Epidemiology and Market Forecast - 2025

Publisher Name :
Date: 01-Nov-2017
No. of pages: 105
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Sickle Cell Disease (SCD) - Market Insights, Epidemiology and Market Forecast-2025" report provides an overview of Sickle Cell Disease, epidemiology and market trend of the Sickle Cell Disease for the United States and EU5 (Germany, Spain, Italy, France and United Kingdom). The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Sickle Cell Disease from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecasted epidemiology of Sickle Cell Disease till 2025.The Report also covers market drivers, market barriers and unmet medical need.

According to DelveInsight, the prevalent population of Sickle Cell Disease is expected to reach up to XXX cases by the end of 2025 at a CAGR of 0.85% from 2015-2025 in 6MM (excluding Japan). High prevalent cases were observed in United States as compared to EU5. The higher prevalence of Sickle Cell Disease in United States is attributed to the immigration of majority of African population in the United States.

Greater uptake by the three emerging novel drugs Endari (Emmaus Lifesciences), GBT-440 (GBT Therapeutics), and Crizanlizumab (Novartis) will primarily drive the SCD market. As the number of effective treatments for the Sickle Cell Disease increase in the market during the forecast period, the prescription medications (HU; Iron Chelators, Analegesics, Antibiotics, vaccines) market share will start to decrease. Emmaus's Endari will be the preferred therapy for the complications associated with SCD owing to its less cost, which will give more patient access to this therapy.

United States contributes the major share of Sickle Cell Disease market as compared to EU5 countries. The therapeutic market of Sickle Cell Disease in 6MM is expected to reach USD 3.1 Billion in 2025 at the CAGR of XX% from 2015-2025.

Key Coverage and Benefits:

- The report will help in developing business strategies by understanding the trends shaping and driving the global Sickle Cell Disease market.

- Organize sales and marketing efforts by identifying the best opportunities for Sickle Cell Disease in US and European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom).

- To understand the future market competition in the Sickle Cell Disease market and Insightful review of the key market drivers and barriers.

- The report provides historical as well as forecasted epidemiology of Sickle Cell Disease in the 6MM covering United States and EU5 (Germany, Spain, Italy, France and United Kingdom) from 2015-2025.

- The Report also covers the detailed historical and forecasted Sickle Cell Disease market covering United States and European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) from 2015-2025.

Sickle Cell Disease - Market Insights, Epidemiology and Market Forecast - 2025

Table of Contents

1. Report Summary
2. Sickle Cell Disease Market Overview at a Glance
2.1. Total Market Share Distribution of Sickle Cell Disease for 6 MM in 2016
2.2. Total Market Share Distribution of Sickle Cell Disease for 6 MM in 2025
3. Disease Background and Overview: Sickle Cell Disease
3.1. Complications of Sickle Cell Disease
3.2. Classification of Sickle Cell Disease
3.3. Causes
3.4. Pathophysiology
3.5. Symptoms
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
5. Prevalent Population of Sickle Cell Disease in 6MM
6. Epidemiology of Sickle Cell Disease
7. United States
7.1. Assumptions and Rationale
7.2. Prevalent Population of Sickle Cell Disease in United States
8. Germany
8.1. Assumptions and Rationale
8.2. Prevalent Population of Sickle Cell Disease in Germany
9. France
9.1. Assumptions and Rationale
9.2. Prevalent Population of Sickle Cell Disease in France
10. Spain
10.1. Assumptions and Rationale
10.2. Prevalent Population of Sickle Cell Disease in Spain
11. Italy
11.1. Assumptions and Rationale
11.2. Prevalent Population of Sickle Cell Disease in Italy
12. United Kingdom
12.1. Assumptions and Rationale
12.2. Prevalent Population of Sickle Cell Disease in United Kingdom
13. Japan
14. Treatment Practices
14.1. Treatment goals
14.2. Treatment Algorithm
14.2.1. Vaso-occlusive crisis: First line treatment
15. Specific pain management
16. Supportive care: Oxygen therapy
17. Hydration: Fluid replacement
18. Antibiotics
19. Transfusions
19.1. Chronic disease
20. First line treatment
21. Hydroxyurea
21.1. Second line treatments
22. Bone marrow transplantation
23. Current Unmet needs
24. Marketed Drugs for Sickle Cell Disease
24.1. Droxia: Bristol-Myers Squibb
24.1.1. Drug Description
24.1.2. Mechanism of Action
24.1.3. Regulatory Milestones
24.1.4. Advantages & Disadvantages
24.1.5. Safety and Efficacy
24.1.6. Product Profile
24.2. Endari: Emmaus Life Sciences, Inc.
24.2.1. Drug Description
24.2.2. Mechanism of Action
24.2.3. Regulatory Milestones
24.2.4. Advantages & Disadvantages
24.2.5. Safety and Efficacy
24.2.6. Product Profile
25. Emerging Drugs for Sickle Cell Disease
25.1. Key Cross Competition
25.2. Recent Safety and Efficacy Results
25.3. Crizanlizumab: Novartis Pharmaceuticals
25.3.1. Regulatory Milestones
25.3.2. Other development activities
25.3.3. Clinical Development
25.3.4. Ongoing Trials Information
25.3.5. Safety and Efficacy
25.3.6. Advantages and Disadvantages
25.3.7. Product Profile
25.4. Rivipansel: Pfizer Inc.
25.4.1. Regulatory Milestones
25.4.2. Other development activities
25.4.3. Clinical Development
25.4.4. Ongoing Trials Information
25.4.5. Safety and Efficacy
25.4.6. Advantages and Disadvantages
25.4.7. Product Profile
25.5. GBT 440: Global Blood Therapeutics, Inc.
25.5.1. Regulatory Milestones
25.5.2. Clinical Development
25.5.3. Ongoing Trials Information
25.5.4. Safety and Efficacy
25.5.5. Product Profile
26. Failed Therapies
26.1. MST-188: Mast therapeutics
26.2. Prasugrel: Eli Lilly & Company
27. Sickle Cell Disease (SCD): Market Analysis
27.1. Key Findings
27.2. Total Market Size of Sickle Cell Disease (SCD) for 6 MM in 2015-2025
27.3. Total Market Size by Therapies
27.4. Total Market Size by Country
28. United States
28.1. Market Size of Sickle Cell Disease (SCD) in United States
29. Europe
30. Germany
30.1. Market Size of Sickle Cell Disease (SCD) in Germany
31. France
31.1. Market Size of Sickle Cell Disease (SCD) in France
32. Italy
32.1. Market Size of Sickle Cell Disease (SCD) in Italy
33. Spain
33.1. Market Size of Sickle Cell Disease (SCD) in Spain
34. United Kingdom
34.1. Market Size of Sickle Cell Disease (SCD) in United Kingdom
35. Market Drivers
36. Market Barriers
37. Appendix
38. Report Methodology
39. Consulting Services
40. Disclaimer
41. About DelveInsight

List of Tables

Table 1: Risk of inheriting Sickle Cell Disease or Sickle Cell Trait
Table 2: Laboratory test schedule for patients with SCD
Table 3: Total Prevalent Population of Sickle Cell Disease in 6 MM (2015-2025)
Table 4: Prevalent Population of Sickle Cell Disease in United States (2015-2025)
Table 5: Prevalent Population of Sickle Cell Disease in Germany (2015-2025)
Table 6: Prevalent Population of Sickle Cell Disease in France (2015-2025)
Table 7: Prevalent Population of Sickle Cell Disease in Spain (2015-2025)
Table 8: Prevalent Population of Sickle Cell Disease in Italy (2015-2025)
Table 9: Prevalent Population of Sickle Cell Disease in United Kingdom (2015-2025)
Table 10: Pharmacological management of pain using WHO three step "Analgesic Ladder"
Table 11: Nonnarcotic Analgesics for Mild Pain in Sickle Cell Disease
Table 12: Common Opioids Used to Treat Mild to Moderate Pain in Sickle Cell Disease
Table 13: Outline of management of acute pain in opioid naïve adults
Table 14: Treatment of Complications
Table 15:Evidence based Management of Sickle Cell disease
Figure 16 : Current Unmet Needs in Sickle Cell Disease
Table 17: List of Marketed Drugs for Sickle Cell Disease
Table 15: Market Size of Sickle Cell Disease (SCD) by Therapies in 6MM (USD Million) (2015-2025)
Table 14: Market Size of Sickle Cell Disease (SCD) in 6MM (USD Million) (2015-2025)
Table 16: United States Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Table 17: Germany Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Table 18: France Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Table 19: Italy Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Table 20:Spain Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Table 21:United Kingdom Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)

List of Figures

Figure 1: Survival of Children with Sickle Cell Disease-Reported by NIH
Figure 2: Complications associated with Sickle Cell Disease
Figure 2: Types of Sickle Cell Disease
Figure 4: Normal vs Sickled Red Blood Cell
Figure 4: Induction of Red-Cell Sickling by Polymerization of Deoxy-hemoglobin-S
Figure 5: Principal Mechanisms Responsible for Potassium and Water Loss in Sickle Red Cells.
Figure 6: Principal Interactions Responsible for the Adhesion of a Sickle Red Cell to the Microvascular Endothelium
Figure 7: Total Prevalent Population of Sickle Cell Disease in 6 MM (2015-2025)
Figure 8: Prevalent Population of Sickle Cell Disease in United States (2015-2025)
Figure 9: Prevalent Population of Sickle Cell Disease in Germany (2015-2025)
Figure 10: Prevalent Population of Sickle Cell Disease in France (2015-2025)
Figure 11: Prevalent Population of Sickle Cell Disease in Spain (2015-2025)
Figure 12: Prevalent Population of Sickle Cell Disease in Italy (2015-2025)
Figure 13: Prevalent Population of Sickle Cell Disease in United Kingdom (2015-2025)
Figure 15: Treatment algorithm for SCD
Figure 16:Measure of pain intensity and location
Figure 15: United States Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Figure 16: Germany Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Figure 17: France Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Figure 18: Italy Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Figure 19: Spain Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Figure 20: United Kingdom Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Figure 21: Market Drivers
Figure 22:Market Barriers
  • Thromboembolism - Pipeline Review, H1 2018
    Published: 18-Jan-2018        Price: US 2000 Onwards        Pages: 67
    Thromboembolism - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H1 2018, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape. When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the......
  • EMEA (Europe, Middle East and Africa) Fibrinogen Concentrate Market 2017 Forecast to 2022
    Published: 18-Jan-2018        Price: US 4480 Onwards        Pages: 118
    Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen Concentrate is used as a medicine for blood disease. Fibrinogen concentrate is a preparation of coagulation factors prepared from pooled plasma. Also known as "fibrin glue" or "fibrin sealant", the majority of available formulations contain a mixture of pooled plasma-derived fibrinogen and the enzyme thrombin. Scope of the Report: This report focuses on the Fibrinog......
  • Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Heparin Market 2017 Forecast to 2022
    Published: 17-Jan-2018        Price: US 4880 Onwards        Pages: 117
    Heparin, a highly sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. It can also be used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machine Scope of the Report: This report focuses on the Heparin in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and......
  • Global Intravenous Immunoglobulin (IVIg) Market Research Report 2018
    Published: 16-Jan-2018        Price: US 2900 Onwards        Pages: 107
    In this report, the global Intravenous Immunoglobulin (IVIg) market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Intravenous Immunoglobulin (IVIg) in these regions, from 2013 to 2025 (forecast), covering - North America ......
  • EMEA (Europe, Middle East and Africa) Intravenous Immunoglobulin (IVIg) Market 2017 Forecast to 2022
    Published: 12-Jan-2018        Price: US 4480 Onwards        Pages: 123
    Intravenous Immunoglobulin, also called gamma globulin or antibodies, is a highly purified blood product preparation that is derived from large pools of plasma donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or "lot" of Intravenous Immunoglobulin. Scope of the Report: This report focuses on the Intravenous Immunoglobulin (IVIg) in EMEA market, covering Europe, Middle East and Africa, This report categorizes the market based on manufacturers......
  • Global Intravenous Immunoglobulins Sales Market Report 2017
    Published: 04-Jan-2018        Price: US 4000 Onwards        Pages: 111
    In this report, the global Intravenous Immunoglobulins market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Intravenous Immunoglobulins for these regions, from 2012 to 2022 (forecast), covering - United States - China - Eu......
  • Global Antithrombotic Drugs Market Size, Status and Forecast 2025
    Published: 03-Jan-2018        Price: US 3300 Onwards        Pages: 95
    This report studies the global Antithrombotic Drugs market, analyzes and researches the Antithrombotic Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Sanofi - Bayer - Boehringer Ingelheim - Genentech - Eli Lilly - Johnson & Johnson - Medicines Company - Pfizer - Otsuka - Reddy's Laboratories Marke......
  • United States Hemophilia A Drug Market Report 2017
    Published: 03-Jan-2018        Price: US 3800 Onwards        Pages: 113
    In this report, the United States Hemophilia A Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate o......
  • United States Hemophilia A Drug Market Report 2018
    Published: 01-Jan-2018        Price: US 3800 Onwards        Pages: 113
    In this report, the United States Hemophilia A Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate o......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs